Eli Lilly and Company (NYSE:LLY) Shares Bought by Field & Main Bank

Field & Main Bank grew its holdings in Eli Lilly and Company (NYSE:LLY) by 9.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,722 shares of the company’s stock after purchasing an additional 668 shares during the quarter. Eli Lilly and Company makes up approximately 1.9% of Field & Main Bank’s portfolio, making the stock its 11th largest holding. Field & Main Bank’s holdings in Eli Lilly and Company were worth $4,501,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its holdings in shares of Eli Lilly and Company by 5.1% during the third quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 3,514 shares of the company’s stock worth $1,887,000 after buying an additional 170 shares in the last quarter. Lantz Financial LLC grew its stake in Eli Lilly and Company by 9.8% in the 3rd quarter. Lantz Financial LLC now owns 1,219 shares of the company’s stock worth $655,000 after acquiring an additional 109 shares during the period. Covenant Partners LLC raised its holdings in Eli Lilly and Company by 101.4% in the 3rd quarter. Covenant Partners LLC now owns 1,003 shares of the company’s stock valued at $539,000 after acquiring an additional 505 shares during the last quarter. Bfsg LLC acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $564,000. Finally, Lake Street Financial LLC lifted its stake in shares of Eli Lilly and Company by 1.9% during the 3rd quarter. Lake Street Financial LLC now owns 7,740 shares of the company’s stock worth $4,214,000 after purchasing an additional 147 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 0.5 %

LLY traded up $3.82 on Monday, reaching $737.33. The company’s stock had a trading volume of 2,726,536 shares, compared to its average volume of 3,017,770. Eli Lilly and Company has a 1 year low of $392.26 and a 1 year high of $800.78. The business’s 50 day moving average is $760.89 and its 200 day moving average is $668.00. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a market cap of $700.58 billion, a price-to-earnings ratio of 127.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.09 earnings per share. As a group, research analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday, April 15th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Finally, Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.